Table 2.

Identification of gag mimetope peptides presented via αhDECp24

Patient	Reactive p24 peptides pool	Active p24 peptide in pool		HLA class I
		No.	Sequence	A1	A2	B1	B2	C1	C2
LB02	I	10	FVEKAFSPEVIPMFSAL	2010	3201	4001	5701	0304	0602
LB03	III	5	AGTTSTLQEQIGWMT	0202	3601	5301	5701	0401	0401
		6	STLQEQIGWMTNNPP
LB04	I	10	EKAFSPEVIPMFSAL	0301	1101	3501	5701	0401	0401
LB05	III	5	AGTTSTLQEQIGWMT	3101	3303	5801	7801	0701	1601
		6	STLQEQIGWMTNNPP
	IV	7	FRDYVDRFYKTLRAE
		8	VDRFYKTLRAEQASQ
LB06	III	9	NPPIPVGEIYKRWII	2301	7401	0801	1801	0304	0202
		10	PVGEIYKRWIILGLN
LB07	III	11	IYKRWWIILGLNKIVR	0301	1101	0702	0733	0702	0704
	V	8	EMMTACQGVGGPGHK
		9	ACQGVGGPGHKARVL
LB10	II	10	AAEWDRLHPVHAGPI	2402	6601	1503	3501	0401	0401
		11	DRLHPVHAGPIAPGQ
LB11	II	9	INEEAAEWDRLHPVH	3201	3201	1402	4002	0802	0202
		10	AAEWDRLHPVHAGPI

As in Table 1 and Fig. 4, gag peptides were identified that were recognized by CD8⁺ T cells after proliferation in response to αDEC p24. We first identified a pool of gag peptides (column 2), and then the peptide pool was broken down into individual peptides to identify the optimal mimetope (columns 3 and 4). After typing for HLA class I alleles at HLA-A, B, and C loci for each patient, we were able to identify from the Los Alamos database (www.hiv.lanl.gov/content/index) known peptide sequences that are presented on a corresponding HLA product in bold and, in one case (patient LB07), a second peptide (underlined).